



GLOBAL ACADEMY *of* WOMEN'S CANCER

EUROPEAN
HYBRID MEETING

Simply the Best Education
you can get

13/14 JUNE
2025
MUNICH
GERMANY

PRELIMINARY PROGRAMME

Updated 14.04.2025

global-academy-of-womens-cancer.org

CONTENT

Welcome Message	•	3
Programme at a Glance	•	4–5
Programme Friday, June 13 th	•	6–10
Programme Saturday, June 14 th	•	12–17
Satellite Symposia Overview	•	18–19
Executive Board	•	20
Invited Faculty	•	21–23
Floor Plan	•	24
General Information	•	25–26

The Global Academy of Women's Cancer – European Hybrid Meeting 2025
is supported by



Berufsverband Niedergelassener und
ambulant tätiger Gynäkologischer Onkologen
in Deutschland e.V.



Dear Colleagues and Friends,

Welcome to Munich!

Following four successful international meetings, we are excited to return to Munich with the 5th edition of the GAWC!

Over the next two days, you will have the opportunity to attend keynote lectures, debates, Meet the Experts sessions, multi-disciplinary panel discussions, case discussions, and sessions on hot topics. During this 2-day meeting in Munich, international experts will summarize, discuss, and present the latest results and treatment strategies.

This interactive congress offers a comprehensive overview of all new developments in breast and gynaecological cancers, which account for 50% of all cancers in women. You will have the chance for direct exchange with the world's leading experts in these fields. Our goal is to present the latest scientific findings in practical recommendations for everyday clinical practice.

We invite you to actively participate in the event! Join us to exchange ideas with your colleagues and experts from around the world, broaden your knowledge, and take away ideas and recommendations for your daily work.

We warmly welcome you in Munich and look forward to an enriching experience together!

Andreas du Bois, MD
Scientific Chair

Jonathan Ledermann, MD
Scientific Chair

Sherko Kümmel, MD
Scientific Chair

Peter Schmid, MD
Scientific Chair

Nadia Harbeck, MD
Local Scientific Chair

Sven Mahner, MD
Local Scientific Chair

Philipp Harter, MD
Local Scientific Chair

PROGRAMME AT A GLANCE

Friday, June 13th

	MAIN ROOM	PARALLEL ROOM
8:00	08:00–09:00 MEET THE EXPERTS SESSIONS Interactive sessions before the event	
9:00	OPENING OF THE CONFERENCE	
	JOINT LECTURE I	
10:00	SATELLITE SYMPOSIUM I PLATINUM	
11:00	ORAL COMMUNICATION I	
12:00	LUNCH BREAK	
13:00	BREAST CANCER SESSION I	GYNAE-ONCOLOGY SESSION I
14:00		
	BREAK	
15:00	SATELLITE SYMPOSIUM II	
16:00	JOINT LECTURE II	
17:00	SATELLITE SYMPOSIUM III	
18:00	BREAST CANCER SESSION II	GYNAE-ONCOLOGY SESSION II
19:00		
20:00		

PROGRAMME AT A GLANCE

Saturday, June 14th

	MAIN ROOM	PARALLEL ROOM
8:00	08:00–08:30 MEET THE EXPERTS SESSIONS Interactive sessions before the event	
9:00	BREAST CANCER SESSION III	GYNAE-ONCOLOGY SESSION III
10:00		
	COFFEE BREAK	
11:00	SATELLITE SYMPOSIUM IV	
	SATELLITE SYMPOSIUM V	
12:00		
	ORAL COMMUNICATION II	
13:00	LUNCH BREAK	
	SATELLITE SYMPOSIUM VI	
14:00		
	BREAST CANCER SESSION IV	GYNAE-ONCOLOGY SESSION IV
15:00		
16:00		
	JOINT LECTURE III	
17:00		
	CLOSING REMARKS AND FAREWELL	
18:00		
19:00		
20:00		

PROGRAMME

Friday, June 13th

08:00–09:00

MEET THE EXPERTS SESSIONS

08:00–09:00 GYN I	Decision making in Endometrial Cancer 2025 Viola Heinzelmann, Basel, Switzerland Richard Schwameis, Vienna, Austria Mansoor Raza Mirza, Copenhagen, Denmark	ROOM 1
08:00–09:00 GYN II	Surgical aspects in advanced Endometrial cancer Sven Mahner, Munich, Germany Philipp Harter, Essen, Germany	ROOM 2
08:00–09:00 GYN III	How to build a (surgical) career in Gynae-Oncology (in Europe) Irina Tsibulak, Innsbruck, Austria Christoph Grimm, Vienna, Austria	ROOM 3
08:00–09:00 Breast I	Management of immune-related adverse events Peter Schmid, London, United Kingdom Melissa Phillips, London, United Kingdom	ROOM 4
08:00–09:00 Breast II	Current topic and standards in breast surgery after neoadjuvant therapy Jens-Uwe Blohmer, Berlin, Germany Stefan Paepke, Berlin, Germany	ROOM 5
08:00–09:00 Breast III	Herausforderung Therapieadhärenz – Klinik meets Praxis (German Session) Jörg Schilling, Berlin, Germany Steffi Busch, Muehlhausen, Germany	ROOM 6

09:10–09:20

MAIN ROOM

WELCOME AND OPENING

Andreas du Bois, Essen, Germany
Sven Mahner, Munich, Germany
Sherko Kümmel, Essen, Germany
Nadia Harbeck, Munich, Germany

09:20–10:00

MAIN ROOM

JOINT LECTURE I

CHAIRS: ANDREAS DU BOIS, ESSEN, GERMANY
NN

09:20–09:40	My personal Highlights of the year in Breast Oncology Stephen Johnston, London, United Kingdom
09:40–10:00	My personal Highlights of the year in Gynae-Oncology Nicoletta Colombo, Milan, Italy

10:05–11:05

SATELLITE SYMPOSIUM I

Friday, July 13th

11:10–11:30

MAIN ROOM

ORAL COMMUNICATION I

BEST OF GYNAE-ONCOLOGY PAPERS

CHAIRS: JONATHAN LEDERMANN, LONDON, UNITED KINGDOM
SVEN MAHNER, MUNICH, GERMANY

11:10–11:20 Oral Communication I

11:20–11:30 Oral Communication II

11:30–12:30

LUNCH BREAK

12:30–14:30

PARALLEL ROOM

GYNAE-ONCOLOGY SESSION I

SURGICAL ASPECTS OF OVARIAN CANCER

CHAIR, MODERATOR AND CASE PRESENTER: CHRISTINA FOTOPOULOU, LONDON

MODERATED INTERACTIVE CASE DISCUSSION I

12:30–13:30 LGSOC Stage FIGO IIIA in a young patient wanting to have children

1. fertility sparing in LGSOC

Nicoletta Colombo, Milan, Italy

Patient gave birth to two children and after 5 years relapsed

2. treatment of relapsed LGSOC: surgery?

Philipp Harter, Essen, Germany

Patient underwent successful surgery but relapsed 2 years

3. systemic treatment of relapse

David SP Tan, Singapore

LECTURES

MODERATORS: LUIS CHIVA, NAVARRA, SPAIN
PHILIPPE MORICE, PARIS, FRANCE
GIOVANNI ALETTI, MILANO, ITALY

13:30–13:45 Breaking News: the TRUST study

Sven Mahner, Munich, Germany

13:45–14:05 Keynote Lecture I: Putting TRUST into perspective

Andreas du Bois, Essen, Germany

14:05–14:20 Surgery in recurrent ovarian cancer: the SuROC-CON

Christina Fotopoulou, London, United Kingdom

14:20–14:30 What does SuROC-CON add to the DESKTOP, SOC-1 and GOG 213 evidence?

Oliver Zivanovic, Heidelberg, Germany

Friday, June 13th

12:30–14:30

MAIN ROOM

BREAST CANCER SESSION I

HR+/- Early Breast Cancer

CHAIRS: NADIA HARBECK, MUNICH, GERMANY
MICHAEL GNANT, VIENNA, AUSTRIA

KEYNOTE LECTURES

- 12:30–12:50 Keynote Lecture I-a: who benefits from Chemotherapy?
Peter Schmid, London, United Kingdom
- 12:50–13:10 Keynote Lecture I-b: Adjuvant CDK4/6i.: For who, how long, what Agent?
Nadia Harbeck, Munich, Germany
- 13:10–13:30 Keynote Lecture II: Optimal Endocrine Therapy in Premenopausal and Postmenopausal Women.
Michael Gnant, Vienna, Austria

MODERATED INTERACTIVE CASE DISCUSSIONS

CHAIR AND MODERATOR: WOLFGANG JANNI, ULM, GERMANY

- 13:30–13:42 a) Perimenopausal intermediate risk (pN1) – with or without endocrine response – optimal strategy?
Sherko Kümmel, Essen, Germany
- 13:42–13:54 b) N0 – intermediate risk – Ribociclib or Chemo or both?
Nadia Harbeck, Munich, Germany
- 13:54–14:06 c) Premenopausal N0 – which strategy?
Peter Schmid, London, United Kingdom
- 14:06–14:18 d) Postmenopausal high-risk and Osteoporosis – Which Chemo regimen and which endocrine therapy?
Michael Gnant, Vienna, Austria
- 14:18–14:30 e) BRCAmut. – Stage II – Ki-67 10%, ER/PR high – what is the optimal strategy?
Stephen Johnston, London, United Kingdom
- Panel discussion:
Nadia Harbeck, Stephen Johnston, Peter Schmid, Sherko Kümmel, Michael Gnant

14:30–15:00

BREAK

15:00–16:00

MAIN ROOM

SATELLITE SYMPOSIUM II

Friday, June 13th

16:00–17:00

MAIN ROOM

JOINT LECTURE II

CHAIRS: PHILIPP HARTER, ESSEN, GERMANY
NICOLAS TURNER, LONDON, UNITED KINGDOM

- 16:00–16:20 Special Lecture I: Multidisciplinary management of brain metastases
John Conibear, London, Germany
- 16:20–16:40 Keynote Lecture: The Present and Future of DNA Damage Repair
Jonathan Ledermann, London, United Kingdom
- 16:40–17:00 Special Lecture II: Role of liquid biopsy in treatment selection of Early and Metastatic Breast Cancer
Nicolas Turner, London, United Kingdom

17:00–17:45

MAIN ROOM

SATELLITE SYMPOSIUM III

17:45–19:00

PARALLEL ROOM

GYNAE-ONCOLOGY SESSION II

CHAIR AND MODERATOR: MANSOOR RAZA MIRZA, COPENHAGEN, DENMARK
CO-CHAIR AND DISCUSSANT: JALID SEHOULI, BERLIN, GERMANY

MODERATED INTERACTIVE CASE DISCUSSION II

- 17:45–18:05 A patient with locally advanced Cervical Cancer and 1 positive pelvic lymph node
1. NACT or not?
Mary McCormack, London, United Kingdom
- 18:05–18:25 A patient received neoadjuvant therapy and was scheduled for chemoradiation
2. Chemoradiation with or without Immune checkpoint inhibitors?
Jonathan Ledermann, London, United Kingdom
- 18:25–18:45 A patient had a moderately good response, but a suspicious lesion on PET CT – suggested persistent disease after chemoradiotherapy?
3. Management of persistent disease
Luis Chiva, Navarra, Spain
- 18:45–19:00 Special lecture: How can we better integrate with patient advocates and charity organizations ?
Jalid Sehouli, Berlin, Germany

Friday, June 13th

17:45–19:10

MAIN ROOM

BREAST CANCER SESSION II

HR+ Metastatic Breast Cancer

CHAIRS: STEPHEN JOHNSTON, LONDON, UNITED KINGDOM
KOMAL JHAVERI, NEW YORK, UNITED STATES

- 17:45–17:55 Keynote Lecture III: Understanding Endocrine Resistance
Stephen Johnston, London, United Kingdom
- 17:55–18:10 State of the Art Lecture I: First-line endocrine-based therapy in the era of adjuvant CDK4/6 inhibitors
Komal Jhaveri, New York, United States
- 18:10–18:25 State of the Art Lecture II: Endocrine-based options in 2nd line and beyond
Virginia Kaklamani, San Antonio, United States
- 18:25–18:40 State of the Art Lecture III: Optimal setting and sequencing of ADC's
Hope S. Rugo, San Francisco, United States

MODERATED INTERACTIVE CASE DISCUSSIONS

MODERATOR: NADIA HARBECK, MUNICH, GERMANY

- 18:40–18:50 Progression on/after CDK4/6 in the adjuvant setting
Hope S. Rugo, San Francisco, United States
- 18:55–19:05 Mixed Response during ADC treatment at MBC HR+
Virginia Kaklamani, San Antonio, United States
- Panel discussion:
Hope S. Rugo, Nicolas Turner, Virginia Kaklamani, Peter Schmid, Komal Jhaveri, Stephen Johnston
- 19:05–19:10 Summary Day 1: HR+: My take home message on one slide
Peter Schmid, London, United Kingdom

Saturday, June 14th

08:00–08:30

MEET THE EXPERTS SESSIONS

08:00–08:30	Wire, Clips, Localizer – Best option for marking the tumor and lymph node	ROOM 1
BREAST IV	Marc Thill, Frankfurt, Germany Mattea Reinisch, Mannheim, Germany	
08:00–08:30	New treatment paradigms in HER 2 low disease	ROOM 2
BREAST V	Giuseppe Curigliano, Milan, Italy	
08:00–08:30	Best management of effects of ADC's	ROOM 3
BREAST VI	Hope Rugo, San Francisco, United States Rupert Bartsch, Vienna, Austria	
08:00–08:30	Management of endocrine related side effects	ROOM 4
BREAST VII	Rachel Würstlein, Munich, Germany Petra Voß, Essen, Germany	
08:00–08:30	Systemic treatment of relapsed ovarian cancer	ROOM 5
GYN IV	Jonathan Ledermann, London, United Kingdom Nicoletta Colombo, Milan, Italy Antonio González-Martin, Madrid, Spain	
08:00–08:30	Surgery in recurrent non-high-grade serious ovarian cancer	ROOM 6
GYN V	Christina Fotopoulou, London, United Kingdom Philippe Morice, Paris, France Andreas du Bois, Essen, Germany	

08:40–10:30

PARALLEL ROOM

GYNAE-ONCOLOGY SESSION III

CHAIR AND MODERATORS: DAVID SP TAN, SINGAPORE
NICOLETTA COLOMBO, MILAN, ITALY

OXFORD DEBATE

08:40–10:30 Non-dMMR advanced endometrial cancer:
Immune checkpoint inhibitors for all patients?
pro: Mansoor Raza Mirza, Copenhagen, Denmark
con: Antonio González-Martin, Madrid, Spain

CASE DISCUSSION

09:30–09:50 1stline maintenance treatment of LGSOC(?)
Philipp Harter, Essen, Germany

09:50–10:10 2ndline treatment of a patient with relapse during PARPi maintenance
therapy and a TFIp of 7 months
Christian Marth, Innsbruck, Austria

10:10–10:30 The impact of a BRCA mutation on surgical decision-making in ovarian cancer
Christina Fotopoulou, London, United Kingdom

Saturday, June 14th

08:40–10:30

MAIN ROOM

BREAST CANCER SESSION III

Her2 Overexpressing

CHAIRS: RUPERT BARTSCH, VIENNA, AUSTRIA
CARLOS BARRIOS, PORTO ALEGRE, BRAZIL

08:40–08:55 Keynote Lecture IV: When to escalate in the adjuvant or postneoadjuvant setting?

Carlos Barrios, Porto Alegre, Brazil

08:55–09:10 Keynote Lecture V: When to de-escalate in the adjuvant or postneoadjuvant setting?

Javier Cortes, Barcelona, Spain

09:10–09:30 Keynote Lecture VI: MBC: Her2 Overexpression – Optimal Sequencing of current treatment options

Nadia Harbeck, Munich, Germany

MODERATED INTERACTIVE CASE DISCUSSIONS

CHAIR AND MODERATOR: NADIA HARBECK, MUNICH, GERMANY

09:30–09:50 a) Triple positive Stage I – with or without chemo?

Carlos Barrios, Porto Alegre, Brazil

09:50–10:10 b) Breast Lesion Her2:+2 (FISH neg.) – axillary Lymph node Her2:+3

Marc Thill, Frankfurt, Germany

10:10–10:30 c) Biopsie of Livermets Her2:+2 (FISH neg.) after EBC with Her2 overexpression

Rupert Bartsch, Vienna, Austria

Panel discussion:

Nadia Harbeck, Javier Cortes, Hope S. Rugo, Marc Thill, Rupert Bartsch, Carlos Barrios

10:30–10:50

COFFEE BREAK

10:50–11:35

MAIN ROOM

SATELLITE SYMPOSIUM IV

11:40–12:10

MAIN ROOM

SATELLITE SYMPOSIUM V

PROGRAMME

Saturday, June 14th

12:10–12:40

MAIN ROOM

ORAL COMMUNICATION II

Best of breast-oncology papers

CHAIRS: WOLFGANG JANNI, ULM, GERMANY
KOMAL JHAVERI, NEW YORK, UNITED STATES

12:10–12:20 Oral Communication III

12:20–12:30 Oral Communication IV

12:30–12:40 Poster Award Ceremony
Mansoor Raza Mirza, Copenhagen, Denmark
NN

12:40–13:25

LUNCH BREAK

13:25–14:10

MAIN ROOM

SATELLITE SYMPOSIUM VI

Saturday, June 14th

14:10–16:10

PARALLEL ROOM

GYNAE-ONCOLOGY SESSION IV

CHAIRS: PHILIPP HARTER, ESSEN, GERMANY
VIOLA HEINZELMANN, BASEL, SWITZERLAND

KEYNOTE LECTURE II

14:10–14:30 Treatment of recurrent clear cell gynaecological cancers
David SP Tan, Singapore

DEBATE

CHAIR AND MODERATOR: JONATHAN LEDERMANN, LONDON, UNITED KINGDOM

14:30–15:10 Patients with newly diagnosed HRD-negative ovarian cancer should be treated with PARPi maintenance
pro: Mansoor Raza Mirza, Copenhagen, Denmark
con: Frederic Marmé, Mannheim, Germany

CASE DISCUSSION

CHAIRS AND MODERATORS: NICOLETTA COLOMBO, MILAN, ITALY
OLIVER ZIVANOVIC, HEIDELBERG, GERMANY

15:10–15:30 A case with a uterine sarcoma
Luis Chiva, Navarra, Spain

15:30–15:50 A case with recurrent cervical cancer progressing after chemoradiotherapy plus Immune Checkpoint Inhibition
Christian Marth, Innsbruck, Austria

15:50–16:10 A case with Her2neu IHC 2+ recurrent endometrial cancer
Antonio González-Martin, Madrid, Spain

Saturday, June 14th

14:10–16:15

MAIN ROOM

BREAST CANCER SESSION IV

Triple Negative Breast Cancer

CHAIRS: GIUSEPPE CURIGLIANO, MILAN, ITALY
NN

KEYNOTE LECTURE VII

14:10–14:25 Lessons learned from immunotherapy in breast cancer
Peter Schmid, London, United Kingdom

HOT TOPICS

14:25–14:40 What to do with patients with residual disease after neoadjuvant therapy
Giuseppe Curigliano, Milan, Italy

14:40–14:55 Can we de-escalate treatment according to response?
Sherko Kümmel, Essen, Germany

KEYNOTE LECTURE VIII

14:55–15:10 MBC: TNBC – Optimal Sequencing of current treatment options
NN

CASE AND PANEL DISCUSSION III

CHAIR AND MODERATOR: PETER SCHMID, LONDON. UNITED KINGDOM

15:10–15:25 Postneoadjuvant – BRCA pos. or neg. – best treatment options?
NN

15:25–15:40 Stage IIa – after 12 weeks cCR – a) pCR, b) RCB 1 – best treatment options?
Oleg Gluz, Monchengladbach, Germany

15:40–15:55 MBC-OMD – bone only TNBC – best treatment options?
Michael Braun, Munich, Germany

15:55–16:10 MBC-OMD – CIT (bone, liver) – 1 new bone lesion – Liver SD-best treatment options?
Peter Schmid, London, United Kingdom

Panel Discussion:

Oleg Gluz, Michael Braun, Giuseppe Curigliano, Sherko Kümmel

16:10–16:15 Summary Day 2: Her2 and TNBC : My take home message on two slides
Peter Schmid, London, United Kingdom

Saturday, June 14th

16:15–17:35

MAIN ROOM

JOINT LECTURE III

Special tutorial

CHAIRS AND MODERATORS: ANDREAS DU BOIS, ESSEN, GERMANY
NN

16:15–17:35 Antibody-Drug Conjugates in Breast Cancer

NN

Antibody-Drug Conjugates in Gynecological Cancers

Philipp Harter, Essen, Germany

Management of ADC toxicity

Hope S. Rugo, San Francisco, United States

Frederik Marmé, Mannheim, Germany

17:35

FAREWELL

SATELLITE SYMPOSIA OVERVIEW

Friday, June 13th

10:05–11:05 SATELLITE SYMPOSIUM I

15:00–16:00 SATELLITE SYMPOSIUM II

17:00–17:45 SATELLITE SYMPOSIUM III



Saturday, June 14th

10:50–11:35 SATELLITE SYMPOSIUM IV

11:40–12:10 SATELLITE SYMPOSIUM V

13:25–14:10 SATELLITE SYMPOSIUM VI

EXECUTIVE BOARD

Initiators of the Global Academy of Women's Cancer

Andreas du Bois, MD
Essen, Germany

Jonathan Ledermann, MD
London, United Kingdom

Sherko Kümmel, MD
Essen, Germany

Peter Schmid, MD
London, United Kingdom

Scientific Board Gynaecological Oncology

Nicoletta Colombo, MD
Milan, Italy

Mansoor Raza Mirza, MD
Copenhagen, Denmark

Christina Fotopoulou, MD
London, United Kingdom

David SP Tan, MD
Singapore

Antonio González-Martin, MD
Madrid, Spain

Philipp Harter, MD
Essen, Germany

Scientific Board Breast Cancer

Carlos Barrios, MD
Porto Alegre, Brazil

Rebecca Dent, MD
Singapore

Javier Cortes, MD
Barcelona, Spain

Nadia Harbeck, MD
Munich, Germany

Giuseppe Curigliano, MD
Milan, Italy

Hope S. Rugo, MD
San Francisco, USA

A

Giovanni Aletti, MD

IEO – Istituto Europeo di Oncologia
Via Ripamonti, 435
20141 Milan, Italy

B

Carlos Barrios, MD

Hospital Sao Lucas
Porto Alegre
Brazil

Rupert Bartsch, MD

Clinical Research Unit,
Clinical Department of Oncology
Department of Internal Medicine I,
Medical University of Vienna
Währinger Gürtel 18–20
1090 Vienna, Austria

Jens-Uwe Blohmer, MD

Campus Charité Mitte
Charitéplatz 1
10117 Berlin, Germany

Michael Braun, MD

Rotkreuzklinikum München
Frauenklinik
Taxisstraße 3
80637 Munich, Germany

Steffi Busch, MD

Spezialized oncological practice
Bei der Marienkirche 6
99974 Muehlhausen, Germany

C

Luis Chiva, MD

Ob-Gynecology at Clinica
Universidad de Navarra
Navarra, Spain

Nicoletta Colombo, MD

Divisione di Ginecologia
Oncologia Medica
IRCCS Istituto Europeo di Oncologia
Via Ripamonti 435
20144 Milan, Italy

John Conibear, MD

Cromwell Hospital
London, United Kingdom

Javier Cortes, MD

Vall d'Hebron Institute of
Oncology, Centro Cellex
Carrer de Natzalet, 115–117
08035 Barcelona, Spain

Giuseppe Curigliano, MD

University of Milan
Via Ripamonti, 435 – IEO – Istituto
Europeo di Oncologia
20141 Milan, Italy Milan Italy

D

Andreas du Bois, MD

Essen-Mitte Evangelical Hospitals
Huyssens Foundation Essen-Huttrop
Clinic for Gynecology and
Gynecologic Oncology
Henricistr. 92
45136 Essen, Germany

F

Christina Fotopoulou, MD

Imperial College London
Hammersmith Hospital
Du Cane Road, W12 7BH
London, United Kingdom

G

Oleg Gluz, MD

Breast Center Niederrhein
Ludwig-Weber-Straße 15
41061 Monchengladbach
Germany

Michael Gnant, MD

Medical University of Vienna
Breast Health Center
Waehringuer Guertel 18–20
1090 Vienna, Austria

Antonio González-Martin, MD

Servicio de Oncologia Medica
Clinica Universidad de Navarra
Avenida P o XII, 36
31008 Madrid, Spain

Christoph Grimm, MD

Clinic for Gynecology Medical
University Vienna
Vienna, Austria

H

Nadia Harbeck, MD

Women's clinics Großhadern
and Maistrasse-Innenstadt
Breast Center of the University
of Munich
Marchioninstr. 15
81377 Munich, Germany

Philipp Harter, MD

Essen-Mitte Evangelical Hospitals,
Huyssens Foundation
Essen-Huttrop
Clinic for Gynecology and
Gynecologic Oncology
Henricistr. 92
45136 Essen, Germany

Viola Heinzelmann, MD

University Hospital Basel
Department of Clinical Research
University of Basel c/o University
Hospital Basel
Spitalstrasse 8/12
new building 2nd floor
CH-4031 Basel, Switzerland

J

Wolfgang Janni, MD

Ulm University Hospital
Prittwitzstr. 43
89075 Ulm, Germany

Komal Jhaveri, MD

Memorial Sloan Kettering
Cancer Center
New York, United States

Stephen Johnston, MD

The Royal Marsden NHS
Foundation Trust & The
Institute of Cancer Research
London, United Kingdom

K

Virginia Kaklamani, MD
UT Health San Antonio MD Anderson
Cancer Center
San Antonio, United States

Sherko Kümmel, MD
Essen-Mitte Evangelical Hospitals
Huyssens Foundation
Essen-Huttrup
Clinic for Gynecology and
Gynecologic Oncology
Henricistr. 92
45136 Essen, Germany

L

Jonathan Ledermann, MD
Clinical Director, UCL Cancer Institute
Department of Oncology
72 Huntley Street
London WC1E 6DD
London, United Kingdom

M

Sven Mahner, MD
LMU Hospital, Clinic and Polyclinic
for Obstetrics and Gynecology,
Campus Großhadern
and City Center – Maistrasse
Marchioninistr. 15
81377 Munich, Germany

Frederik Marmé, MD
University Medical Center Mannheim
Theodor-Kutzer-Ufer 1–3
68167 Mannheim, Germany

Christian Marth, MD
Medical University of Innsbruck,
University Clinic for Gynecology and
Obstetrics
Anichstr. 35
6020 Innsbruck, Austria

Mary McCormack, MD
The Harley Street Clinic,
part of HCA Healthcare UK
London, United Kingdom

Mansoor Raza Mirza, MD
Nordic Society of Gynaecological
Oncology Dept. of Oncology,
Copenhagen
University Hospital
Blegdamsvej 9
2100 Copenhagen, Denmark

Philippe Morice, MD
Institut Gustave Roussy
Department of Medical Oncology
Villejuif, France

P

Stefan Paepke, MD
Klinikum rechts der Isar der TU
München
Ismaninger Straße 22
81675 Munich, Germany

Melissa Phillips, MD
St Bartholomew's Hospital
W Smithfield
London EC1A 7BE, United Kingdom

R

Hope S. Rugo, MD
University of California San
Francisco, UCSF Helen Diller Family
Comprehensive Cancer Center
1450 3rd St., San Francisco
CA 94158 California, USA

Mattea Reinisch, MD
University Women's Hospital
Mannheim
Theodor-Kutzer-Ufer 1–3
68167 Mannheim, Germany

S

Jörg Schilling, MD
Specialized oncological practice
Woennichstr. 64
10317 Berlin

Peter Schmid, MD
Charterhouse Square Campus
Charterhouse Square
London EC1M 5PZ, United Kingdom

Richard Schwameis, MD
Medical University of Vienna
Vienna, Austria

Jalid Sehouli, MD
Charité Universitätsmedizin Berlin
Berlin, Germany

T

David SP Tan, MD
Cancer Science Institute (CSI), 14
Medical Dr 12–01 Centre for
Translational Medicine
117599 Singapore

Marc Thill, MD
AGAPLESION MARKUS HOSPITAL
Wilhelm-Epstein-Straße 4
60431 Frankfurt am Main, Germany

Irina Tsibulak, MD
Medical University of Innsbruck
Innsbruck, Austria

Nicholas Turner, MD
ICR The Institute of Cancer Research
123 Old Brompton Road
London SW7 3RP
United Kingdom

V

Petra Voiß, MD

Essen-Mitte Evangelical Hospitals
 Huyssens Foundation
 Essen-Huttrop
 Clinic for Gynecology and
 Gynecologic Oncology
 Henricistr. 92
 45136 Essen, Germany

W

Rachel Würstlein, MD

Breast Center and CCC Munich
 Department of Gynecology and
 Obstetrics, University Hospital
 Munich, LMU Munich
 Marchioninistr. 15
 81377 Munich, Germany

Z

Oliver Zivanovic, MD

Medical Director of the Clinic
 for Gynaecology and Obstetrics
 at the UKHD, University Clinic
 Heidelberg
 Im Neuenheimer Feld 672
 69120 Heidelberg, Germany



FLOORPLAN



Abstract AWARDS

Mini Oral Presentations: Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives. The 4 best abstracts will be selected to be presented during the oral communication sessions.

Poster Awards: Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work. The 6 best Posters on display will be awarded with 500 € each and a free registration to the next Congress. All prize-winning abstracts will be selected by the Poster & Oral Communication Committee. Further information on when the prizes will be awarded will follow.

CME Credits

The event The Global Academy of Women's Cancer – European Hybrid Meeting, taking place from June 13, 2025, to June 14, 2025, in Munich, Germany, is being submitted for certification.

Congress Date

June 13th–June 14th, 2025

Congress Organization

MEDCONCEPT 

Gesellschaft für medizinische Projekte mbH



Project Manager:

Mrs. Beatrice Schröder

E-Mail: event@medconcept.org

Friedenstr. 58

15366 Neuenhagen bei Berlin, Germany

Phone: +49 (0)3342 42689-13

Fax: +49 (0)3342 42689-40

E-Mail: info@medconcept.org

Internet: www.medconcept.org

Congress Website

<http://www.global-academy-of-womens-cancer.org>

Congress Venue

HOLIDAY INN
MUNICH-CITY CENTRE
Hochstrasse 3
81669 Munich, Germany
Phone: +49 (0)89 4803 3333
Fax: +49 (0)89 4487 170
E-Mail: meeting@himunich.com
www.holidayinn.com/munich

Exhibition

A commercial exhibition will be held at the congress venue, close to the main meeting room.

Exhibition Opening Hours

Friday, June 13, 2025	10:00–19:00
Saturday, June 14, 2025	08:00–17:00

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect health and travel insurance.

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration and Information Desk

The registration desk is situated at the ground floor of the Holiday Inn to the left of the reception and in front of the meeting area entrance.

Registration Desk Opening Hours

Friday, June 13, 2025	07:00–19:00
Saturday, June 14, 2025	07:30–17:30

CONGRESS ON-DEMAND

All approved lectures
from the event will
be available on the
On-Demand platform
from June 16th, 2025 until
September 30th, 2025.

The on-demand service
is available to all registered
attendees (F2F and virtual).

The area
is password
protected

Access to the On-Demand area is granted using the
same login credentials as for the virtual platform.

Together into the future

*Plan with us your next
scientific event*



MedConcept Gesellschaft
für medizinische Projekte mbH
Friedenstraße 58, 15366 Neuenhagen



+49 3342 42689-30



info@medconcept.org



www.medconcept.org

MEDCONCEPT 
Experience since 1997

IMPORTANT INFORMATION

Certificate of Attendances

All registered attendees will receive a certificate of attendance some days after the meeting via e-mail and after completing an evaluation survey.

Please note! If you need to change your contact e-mail address, please come to the registration desk.

Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area.

TED/Polling

Please scan the QR code with your mobile device or visit www.slido.com and enter the event code to participate in the polling.



event code:
#GAWC2025